Article
Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group.
Pharmacopsychiatry - 1 Jul 2024
Maier Hannah B, Borchert Anton, Neyazi Alexandra, Moschny Nicole, Schülke Rasmus, Bundies Gabriel L, Folsche Thorsten, Gaspert Anastasia, Seifert Johanna, Bleich Stefan, Scherf-Clavel Maike, Unterecker Stefan, Deckert Jürgen, Frieling Helge, Weber Heike
Abstract excerpt
BACKGROUND: Approximately 15-25% of depressed patients suffer from difficult-to-treat depression (DTD). Patients with DTD require a thorough examination to avoid the oversight of treatable (psychiatric/somatic) comorbidities or (pseudo-)resistance to antidepressant drugs (ADs). Polymorphisms of the cytochrome P450 (CYP) enzymes 2D6 and 2C19, which play a major role in the metabolism of ADs, may contribute to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.